Ska omsätta 450 mkr år 2027 SaveLend group har annonserat nya finansiella mål som sträcker sig till ...
Duell publishes its Q1 2024 business report on 18th of January.
Redeye comments on yesterday’s news where Tessin has secured short-term funding by issuing a convert...
Redeye provides a research update following the Q1 report published by Newbury yesterday.
Q4 report due 21 Feb Q4'23e net sales SEK 195m, EBITA SEK 25m We raise our fair value range to SEK 2...
Eevia Health Plc's ("Eevia" or "the Company") announced on the 10th of January 2024 that the Company...
Redeye is positive about SenzaGen’s GARDskin order worth SEK1.
Redeye leaves an initial comment following the Q1 report published by Newbury this morning.
Fiskars has completed the purchase price allocation of the Georg Jensen acquisition and recognizes n...
Redeye endorses CLS’ new order of SEK8.1m from ClearPoint Neuro.
Lyckegård Group AB (”Lyckegård” eller ”bolaget”) meddelade den 8 januari år 2024 att bolaget avser r...
Redeye provides an initial comment on Fluoguide communicating a strategic update for FG001’s clinica...
Calliditas published a preliminary Q4 update earlier today.
Redeye takes a positive view on the CEO change in Speqta.
Redeye briefly comments on the announcement of an indication expansion made by Initiator Pharma earl...
Hansa delivers a positive surprise in Q4 as Idefirix records European product sales of SEK 43m in Q4...
Redeye comments on Nito Games' preliminary figures for Q4, which exceed our expectations by 20% on t...
IRLAB Therapeutics has scheduled an end-of-Phase II (EoP2) meeting (on 20 February 2024) with the US...
Redeye in this note briefly comments on the latest happenings in the 879 patent litigation process.
Redeye updates Spago after completion of the recent funding and the initiation of the clinical stage...